This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PHILADELPHIA and REHOVOT,
April 1, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript regarding the development and validation of the Company's microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by
Yael Spector, a scientist from Rosetta Genomics, and Dr.
Eddie Fridman, a pathologist and an expert in urological pathology from Sheba Medical Center in Tel-Hashomer,
Israel, are the lead authors on the manuscript.
An unedited version of the manuscript is available online ahead of print publication of the final article at
The manuscript discusses the development and validation of the miRview
® kidney assay, which differentiates between the four main types of primary kidney tumors: the three subtypes of renal cell carcinoma (RCC) namely clear cell, papillary and chromophobe RCC, and typically benign behaving oncocytoma. The assay was developed on a microarray platform using 181 training samples and validated on an independent set of 201 samples. The assay provided results for 92% of the validation samples, with 95% accuracy.
The topic of this manuscript will also be summarized in a poster to be presented on
April 7 at the American Association for Cancer Research (AACR) Annual Meeting 2013 in
"There are an estimated 65,000 new cases of kidney cancer each year in the U.S. and more than 13,000 deaths. Distinguishing between the four main types of primary kidney tumors is critical in determining the optimal treatment regimen," said
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Our miRview
® kidney assay accurately classifies clear cell RCC, papillary RCC, chromophobe RCC and oncocytoma. We are delighted that this work has been accepted for publication in
Molecular Oncology, an important industry trade journal."
"The classification into subtypes of RCC has historically been less than definitive by histology, cytology and immunohistochemistry particularly in the growing context of fine needle aspirate (FNA) diagnostic specimens. The discrimination of the four subtypes can lead to the avoidance of aggressive surgical intervention in oncocytomas, and the others have differing biological behaviors that can be correlated with subtype. Importantly, newer therapeutic agents may show evidence of specificity of response by cell type. The expanded clarity of RCC diagnosis through the availability of this test will help lead to improved rationalization and optimization of new and emerging therapies, particularly in the community setting," said
Bob Wassman, M.D., Chief Medical Officer of Rosetta Genomics.